Navigation Links
MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
Date:11/14/2007

to common stockholders during the first nine months of 2007 was ($0.78), down from a net loss per share of ($0.93) in the first nine months of 2006.

"We believe the Amoxicillin PULSYS NDA review process has progressed very well thus far and we look forward to continuing to work with the FDA throughout the remainder of their review," stated Edward M. Rudnic, Ph.D., president and CEO of MiddleBrook.

OPERATIONAL HIGHLIGHTS

Amoxicillin PULSYS NDA Review -- PDUFA Date January 23, 2008

On May 22, 2007, MiddleBrook's New Drug Application (NDA) for its once- daily Amoxicillin PULSYS product was accepted for filing by the U.S. Food and Drug Administration (FDA). MiddleBrook has worked closely with the FDA throughout the subsequent review process and anticipates a decision on the application on its Prescription Drug User Fee Act (PDUFA) target action date of January 23, 2008.

Amoxicillin is currently not approved for once-daily dosing to treat pharyngitis. If approved for marketing, physicians prescribing Amoxicillin PULSYS would have available the first once-daily product in the aminopenicillin class for the treatment of pharyngitis while utilizing approximately one-half the amount of amoxicillin currently used. About 15 million patients annually seek relief of sore throat symptoms in the United States.

Keflex(R) Capsules (Cephalexin, USP) -- Commercialization Update

During the third quarter, MiddleBrook continued the commercialization of its 750 mg strength Keflex capsules through a targeted and dedicated national contract sales force and MiddleBrook district sales managers. Based on prescription data from IMS Health, total prescriptions filled for Keflex 750 mg capsules in the third quarter of 2007 were 83,767 prescriptions, up from second quarter 2007 total prescriptions of 82,621.

MiddleBrook recently conducted a review of its Keflex sales initiatives and as a result reduced the size of its sales force to approximately 30 c
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... As obesity rates sky rocket in the ... equipment during childbirth comes as no shock. Forceps are surgical ... when she is unable to do so herself and although ... higher rates of complication for both the mother and the ... mother and child, forceps births add to the pressure of ...
(Date:6/18/2013)... SEATTLE, WA—A Washington state resident filed ... claiming he fell ill with a hepatitis A infection ... blend. The complaint was filed in Snohomish County ... Seattle-based law firm that has filed 14 previous ... complaint, Brian Brothers consumed “Townsend Farms Organic Antioxidant Blend” ...
(Date:6/18/2013)... The Drug Delivery Partnering Terms and Agreements ... drug delivery partnering deals and agreements entered into by ... provides a detailed understanding and analysis of how and ... of deals are discovery or development stage whereby the ... license the license drug delivery technology. These deals tend ...
(Date:6/18/2013)... The Temp1000IS temperature data logger is ... be used to automatically record temperatures between -20 and ... comes with the serial number and device name engraved. ... separately) docking station and can be placed directly into ... of end-caps to download data. The small size of ...
(Date:6/18/2013)... 2013 Parker Waichman LLP , ... of victims injured by defective medical devices, reports that ... Infuse bone graft products are now available. Published this ... the two studies serve up two key findings: There ... Infuse and the traditional bone graft; and there is ...
Breaking Medicine News(10 mins):Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3
... the fight against HIV and they must be given ... a new commentary published today in the journal Nature ... who are evaluating multiple candidate vaccines designed to prevent ... commit to sharing technology and expertise with those in ...
... Tufts University School of Medicine in collaboration with ... created a computer program called Pathogen Simulation (PathSim) ... in humans. David Thorley-Lawson, PhD, professor of pathology ... PathSim, laboratory methods, and clinical studies to provide ...
... MA- Mayor Michael R. Bloomberg of New York ... Julius B. Richmond Award, the highest honor given by ... of bold initiatives that recognize public health as a ... extraordinary leadership in protecting and promoting the health of ...
... is the latest American Chemical Society (ACS) News Service ... journals and Chemical & Engineering News. With more than,160,000 ... the individual journal, or the American Chemical Society, as ... #1 FOR IMMEDIATE RELEASE , , Excess female ...
... at the University of Pennsylvania School of Medicine have ... affecting the prognosis of patients with head and neck ... issue of CANCER. , The belief that a patients ... their cancer is one that has been prominent among ...
... 100,000 California seniors finds too few health tests , ... care received by vulnerable elderly Medicare, Medicaid patients is ... Researchers at the University of California, Los Angeles, used ... of Vulnerable Elders project to look at 43 specific ...
Cached Medicine News:Health News:Fight against HIV needs local scientists, say researchers 2Health News:Epstein-Barr: a virtual look at a vexing virus 2Health News:Bloomberg receives award for promotion of health in NYC and nation 2Health News:Bloomberg receives award for promotion of health in NYC and nation 3Health News:Bloomberg receives award for promotion of health in NYC and nation 4Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 2Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 3Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 4Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 5Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 6Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 7Health News:American Chemical Society's Weekly Presspac -- Oct. 17, 2007 8Health News:Penn researchers find emotional well-being has no influence on cancer survival 2Health News:Most Elderly Don't Get Good Medical Care: Study 2
(Date:6/18/2013)... 18, 2013 Today, Wall Street Reports ... GILD ), Health Management Associates Inc. (NYSE: ... ISIS Pharmaceuticals Inc. (NASDAQ: ISIS ), and Trius ... free of charge - including full price targets, industry analysis ... Gilead Sciences, Inc. Research Report On June 7, ...
(Date:6/18/2013)... , June 18, 2013 Apama ... on the development of next-generation atrial fibrillation technologies, ... 8295902 by the US Patent and Trademark Office ... low profile electrode assemblies for use on expandable ... or other surgical procedures. "We are ...
(Date:6/17/2013)... , June 17, 2013 Velplex, LLC announced ... a technology platform that connects buyers and sellers of ... an industry leader. Why? It,s because ... are intimately familiar with the dental industry. They have ... and have diligently worked to negotiate some of the ...
Breaking Medicine Technology:Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6TopProdeals.com Rises to Top as Discount Dental Supply Leader 2
Sphincter of Oddi Solid State Catheter Adapter Cable for Polygraf ID...
... diagnosis of influenza A and ... due to the availability of ... of influenza using Clearview Exact ... lead to reduced hospital stays, ...
... A1c-Cellular is the first HbA1c control available ... the entire HbA1c procedure including the lysing ... is a ready-to-use liquid control with an ... closed-vial stability of six months when refrigerated. ...
...
Medicine Products: